Clinical Trial Update: The ORTIZ Study: Optimising RASi Therapy With SZC [Phase 2]

View source ↗

Summary

Phase 2 ORTIZ trial evaluating sodium zirconium cyclosilicate (SZC) to optimize renin-angiotensin system inhibitor therapy in CKD and type 2 diabetes with hyper…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Hyperkalemia
• Type 2 Diabetes Mellitus

Drugs mentioned

• Sodium zirconium cyclosilate (sodium zirconium cyclosilicate)

Snippet

Sponsor: Barts & The London NHS Trust | Conditions: CKD, Diabetes Mellitus, Type 2 | Phase 2 | Status: TERMINATED | Results posted: 2025-06-08